DrugPatentWatch Database Preview
Drugs in Development Information for Mibefradil
Development status for investigational drug Mibefradil: Sponsors, patents, clinical trial progress
Mibefradil is an investigational drug.
There have been 5 clinical trials for Mibefradil.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 28th 2018.
The most common disease conditions in clinical trials are Glioma, Central Nervous System Neoplasms, and Dyslipidemias. The leading clinical trial sponsors are Cavion LLC, Instituto Nacional de Salud Publica, Mexico, and National Cancer Institute (NCI).
There are nine hundred and seventy US patents protecting this investigational drug and seven international patents.
Summary for Mibefradil
| US Patents | 970 |
| International Patents | 7,795 |
| US Patent Applications | 1,806 |
| WIPO Patent Applications | 1,131 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 1 (2018-05-28) |
| Vendors | 29 |
Recent Clinical Trials for Mibefradil
| Title | Sponsor | Phase |
|---|---|---|
| Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population | Instituto Nacional de Salud Publica, Mexico | Phase 3 |
| Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population | Laboratorios Grossman, S.A. | Phase 3 |
| TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM | Yale University | Phase 1 |
Clinical Trial Summary for Mibefradil
Top disease conditions for Mibefradil
Top clinical trial sponsors for Mibefradil
US Patents for Mibefradil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Mibefradil | See Pricing | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | See Pricing |
| Mibefradil | See Pricing | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Pricing |
| Mibefradil | See Pricing | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG (Basel, CH) | See Pricing |
| Mibefradil | See Pricing | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Mibefradil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Mibefradil | European Patent Office | 2981556 | 2033-04-02 | See Pricing |
| Mibefradil | World Intellectual Property Organization (WIPO) | 2014165513 | 2033-04-02 | See Pricing |
| Mibefradil | Australia | 2015210983 | 2034-01-30 | See Pricing |
| Mibefradil | Canada | 2934936 | 2034-01-30 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
